

Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS

Mar 22, 2018

Source URL: <https://qa1.novartis.us/us-en/news/media-releases/phase-iii-data-lancet-show-novartis-siponimod-significantly-improved-outcomes-patients-secondary-progressive-ms-0>

List of links present in page

1. <https://qa1.novartis.us/us-en/us-en/news/media-releases/phase-iii-data-lancet-show-novartis-siponimod-significantly-improved-outcomes-patients-secondary-progressive-ms-0>